Federal Register of Legislation - Australian Government

Primary content

PB 117 of 2022 Determinations/Health as made
This instrument amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015) to determine originator brand status for pharmaceutical items of two drug new to the PBS F2 formulary.
Administered by: Health and Aged Care
Registered 30 Nov 2022
Tabling HistoryDate
Tabled HR15-Dec-2022
Tabled Senate06-Feb-2023
Date of repeal 30 Mar 2023
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003
Table of contents.

Commonwealth Coat of Arms of Australia

 

PB 117 of 2022

 

National Health (Originator Brand) Amendment Determination 2022 (No. 5)

 I, Nikolai Tsyganov, Acting Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make the following Determination.

Dated               30 November 2022                 

NIKOLAI TSYGANOV

Acting Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health and Aged Care


 

Contents

1  Name........................................................................................................................................ 1

2  Commencement........................................................................................................................ 1

3  Authority.................................................................................................................................. 1

4  Schedules................................................................................................................................. 1

Schedule 1—Amendments                                                                                           2

National Health (Originator Brand) Determination 2015 (PB 100 of 2015)                            2

 

 


1  Name

                   This instrument is the National Health (Originator Brand) Amendment Determination 2022 (No. 5).

                   This instrument may also be cited as PB 117 of 2022.

2  Commencement

             (1)  Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

 

Commencement information

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1.  The whole of this instrument

 1 December 2022

 

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

             (2)  Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

                   This instrument is made under subsection 99ADB(6B) of the National Health Act 1953.

4  Schedules

                   Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.


Schedule 1Amendments

National Health (Originator Brand) Determination 2015 (PB 100 of 2015)

1  Schedule 1, (after table item 84)

Insert:

84A

Fingolimod

Gilenya

 

 

2  Schedule 1, (after table item 187)

Repeal the item:

188

Polyvinyl Alcohol

Liquifilm Tears

 

 

188A

Posaconazole

Noxafil

 

 

Substitute:

188

Polyvinyl Alcohol

Liquifilm Tears

 

 

188A

Pomalidomide

Pomalyst

 

 

188B

Posaconazole

Noxafil